TATA健康(01255.HK)投資Promethera Therapeutics的協議已吿失效
格隆匯10月27日丨TATA健康(01255.HK)發佈公吿,2021年6月29日,公司的全資附屬公司商贏與共同投資者、共同貸款人、Promethera Biosciences及Promethera Therapeutics訂立投資及股東協議,據此,商贏將認購新股份,相當於Promethera Therapeutics於投資及股東協議交割後即時已發行股本總額的37.61%。
由於投資及股東協議及購股協議的先決條件於最後截止日期前並未達成及╱或獲豁免,投資及股東協議及購股協議已吿失效。由於未能於最後截止日期前簽署正式轉授許可協議,轉授許可協議條款清單已自動終止。投資將不會進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.